A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Melanoma|Non-small Cell Lung Cancer|Breast Cancer|Gastric Cancer|Renal Cell Carcinoma|Ovarian Cancer|Cholangiocarcinoma|Bladder Urothelial Carcinoma|Pancreatic Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Hepatic Cancer|Head and Neck Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Other Solid Tumors|Diffuse Large B-cell Lymphoma (DLBCL)|Mantle Cell Lymphoma|Indolent B-cell Lymphomas|Non-Hodgkin Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Waldenstrom's Disease|Marginal Zone Lymphoma|Mucosa Associated Lymphoid Tissue|Small Lymphocytic Leukemia
Interventions: DRUG: CDX-1140|DRUG: CDX-301|DRUG: Pembrolizumab|DRUG: Chemotherapy
Sponsor: Celldex Therapeutics
Collaborators: Merck Sharp & Dohme LLC